India-made Covid-19 vaccine Covaxin now on UK's approved travel list

Earlier this month, the Bharat Biotech manufactured Covaxin had received its WHO EUL status

Covaxin
Covaxin (Photo: Bloomberg)
Press Trust of India London
1 min read Last Updated : Nov 22 2021 | 9:42 PM IST

Bharat Biotech manufactured Covaxin, one of the vaccines being administered in India to protect against COVID-19, is on the UK's list of approved COVID-19 vaccines for international travellers from Monday.

It will benefit more fully vaccinated Indians planning travel to the UK without the need for a pre-departure PCR test or self-isolation at the address declared on their compulsory Passenger Locator Forms.

Like other fully vaccinated travellers, including those vaccinated with Covishield, they are required to pre-book a PCR or Lateral Flow Test on arrival in England, to be taken before the end of day 2.

"From 4am on Monday 22 November, the government will recognise vaccines on the World Health Organisation's Emergency Use Listing (WHO EUL) at the border," the UK's Department for Transport (DfT) confirmed.

"As a result, Sinovac, Sinopharm Beijing and Covaxin will be added to our existing list of approved vaccine for inbound travel, benefitting more fully vaccinated passengers, it said.

Earlier this month, the Bharat Biotech manufactured Covaxin - the second most used formulation in India - had received its WHO EUL status, resulting in the UK announcing plans to include it on its list of approved COVID vaccines from November 22.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :VaccineBharat BiotechVaccinationCoronavirus Vaccine

First Published: Nov 22 2021 | 9:42 PM IST

Next Story